Three IPOs, Three Very Different Stories

If you have been even loosely tracking the primary market this month, you already know August 2026 has been unusually crowded on the mainboard side. Rather than looking at these IPOs one at a time, it is worth putting three of them side by side, because the contrast tells you more than any single listing story would on its own. Hy-Tech Engineers, Symbiotec Pharmalab and Tempsens Instruments have all been in the news this week, and each one is behaving in a completely different way in the grey market.

One is a small issue with an outsized retail frenzy, one is a large pharma play weighed down by a heavy offer for sale, and one has grey market premium climbing so fast it has genuinely surprised even seasoned IPO trackers. Reading them together is a useful exercise in understanding why GMP moves the way it does, rather than treating each number as a standalone fact.

Hy-Tech Engineers: The Small Deal With a Big Retail Frenzy

Hy-Tech Engineers is easily the smallest of the three, a Rs. 135.73 crore book built issue made up of a Rs. 60 crore fresh issue alongside an offer for sale. Despite the modest size, the issue was subscribed close to 19 times, and grey market premium has been sitting around Rs. 30, implying a listing premium in the region of 57 percent over the issue price. We covered the retail frenzy behind this one in more depth separately in our piece on what actually drove the 19 times subscription for Hy-Tech Engineers, which is worth reading if you want the fuller picture on why a relatively small issue generated this much retail appetite.

Symbiotec Pharmalab: The Big Pharma Play Weighed Down by OFS

Symbiotec Pharmalab sits at the opposite end of the size spectrum, a Rs. 1,757 crore issue that opened on August 24 and closes on August 27, with listing expected on both NSE and BSE around September 1. The price band is set at Rs. 938 to Rs. 988 per share, with a lot size of 15 shares. Here is the detail worth flagging clearly though, of that Rs. 1,757 crore, only Rs. 150 crore is a fresh issue, with the remaining Rs. 1,607 crore being an offer for sale from existing shareholders. That is a genuinely large share of the issue simply changing hands rather than bringing new capital into the company itself, and it is worth keeping that distinction in mind rather than just looking at the headline issue size.

The underlying business is a research driven pharmaceutical and biotechnology company incorporated in 2002, with a genuine specialisation in steroidal hormone and corticosteroid APIs, alongside complex injectables, and facilities carrying both US FDA and EU-GMP approvals. Revenue grew from Rs. 755.98 crore in FY25 to Rs. 872.26 crore in FY26, with profit rising from Rs. 96.79 crore to Rs. 109.90 crore over the same period. Grey market premium here has been running around Rs. 370, translating to roughly a 37 percent estimated listing premium, and most broker commentary so far has leaned toward Subscribe with a long term view rather than a purely listing gain focused recommendation.

Tempsens Instruments: The Runaway GMP Story

Tempsens Instruments is the one genuinely surprising every one this week. The issue price was fixed at Rs. 300 per share for this Rs. 650 crore offering, and grey market premium has climbed sharply, moving from around Rs. 154 on August 17 to a high of Rs. 321 on August 22, before easing slightly to Rs. 318 by August 24. At that level, the implied listing premium works out to roughly 106 percent over the issue price, putting the estimated listing price near Rs. 618. Subscription numbers back up the enthusiasm too, with the issue subscribed 60.58 times overall as of midday on August 24.

What is actually driving this is a fairly specific business moat rather than pure hype. Tempsens is the largest manufacturer of contact and non-contact temperature sensors in India by revenue, holding roughly a 10.5 percent share of the domestic temperature sensor segment in FY26. Niche, specialised manufacturing businesses like this one often command disproportionately strong grey market interest precisely because there are so few comparable listed peers for investors to benchmark against.

IPO Snapshot: Issue Size, GMP and Subscription

IPO	Issue Size	GMP-Implied Premium	Subscription
Hy-Tech Engineers	Rs. 135.73 crore	Approx. 57%	Approx. 19 times
Symbiotec Pharmalab	Rs. 1,757 crore	Approx. 37%	Book building in progress
Tempsens Instruments	Rs. 650 crore	Approx. 106%	60.58 times

GMP-Implied Listing Premium, Side by Side

Tempsens GMP: The Week's Sharp Climb

What the GMP Spread Actually Tells You

The gap between 37 percent and 106 percent across two IPOs opening in the same week is not really about one company being better run than the other, it is mostly about supply, scarcity and how much of the issue is actually new money versus existing shareholders cashing out. Symbiotec's large OFS component means a bigger chunk of shares hitting the market from day one, which naturally puts more pressure on grey market pricing compared to a smaller, tightly held issue like Tempsens. We saw a similar dynamic play out recently with the Augmont Enterprises IPO, another sizeable issue where GMP built up steadily but never quite reached the kind of levels Tempsens is showing here.

It is also worth remembering that strong GMP does not automatically mean a smooth listing. Just a few weeks ago we covered the Horizon Industrial Parks IPO, which sits at the complete opposite end of this spectrum with genuinely muted grey market interest, and that contrast is useful precisely because it shows how differently the market can treat two mainboard issues in the same month. We flagged this same caution in our piece on whether GMP hype is actually justified, and the lesson applies just as directly to Tempsens' 106 percent number as it did there.

Should You Chase These GMP Numbers

Grey market premium is genuinely useful as a sentiment indicator, but it is unofficial, untraded, and can compress meaningfully in the days right before listing, especially for an issue like Tempsens where the premium has already more than doubled in a week. Symbiotec's allotment is expected on August 28, with listing following on September 1, so there is still time for its own numbers to shift before the actual outcome is known. Comparing this batch against the broader Rs. 7,681 crore IPO week we tracked a few weeks back, and against how the Shiprocket IPO and the Lumino Industries cable and wire issue played out, is a useful way to build a feel for how differently GMP and actual listing day performance can line up, or not, across a busy IPO month.

Our general framework for evaluating any live issue, covered in more depth in this week's broader IPO watch, applies here too. Look past the GMP number itself and into the underlying business, the OFS versus fresh issue split, and the sector dynamics before deciding where to apply. As always, this is not investment advice, and any application decision should be based on your own research, risk appetite and the actual prospectus rather than the grey market number alone.

Frequently Asked Questions (FAQ)

1. Which of these three IPOs has the highest GMP right now?

Tempsens Instruments currently has the highest GMP-implied listing premium at around 106%, followed by Hy-Tech Engineers at around 57% and Symbiotec Pharmalab at around 37%.

2. Why is Symbiotec Pharmalab's GMP lower despite being the largest issue?

A large portion of the Rs. 1,757 crore issue is an offer for sale rather than a fresh issue, meaning more shares are entering the market from existing shareholders, which tends to put more pressure on grey market pricing compared to smaller, tightly held issues.

3. What does Tempsens Instruments actually manufacture?

Tempsens Instruments is the largest manufacturer of contact and non-contact temperature sensors in India by revenue, holding roughly a 10.5% share of the domestic temperature sensor segment in FY26.

4. When does Symbiotec Pharmalab list on the stock exchanges?

Symbiotec Pharmalab is expected to list on NSE and BSE around September 1, 2026, with allotment expected on August 28, 2026.

5. Is GMP a reliable indicator of actual listing gains?

GMP is an unofficial, untraded indicator of sentiment and can change significantly, sometimes compressing sharply, in the days leading up to actual listing, so it should be treated as a signal rather than a guarantee.